Welcome to our dedicated page for Innate Pharma Sa SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innate Pharma S.A. (IPHA) SEC filings page on Stock Titan provides access to the company’s US regulatory submissions, primarily filed as a foreign private issuer on Form 6-K and Form 20-F-related documents. Innate Pharma is a global, clinical-stage biotechnology company developing antibody-based immunotherapies for cancer, with securities listed on Euronext Paris (IPH) and Nasdaq (IPHA).
Through these filings, Innate Pharma reports information that supplements its press releases and investor communications. Form 6-K reports typically furnish press releases on topics such as business updates, clinical trial progress, financial results, changes in capital structure, and key corporate developments. Some 6-K filings are incorporated by reference into Innate Pharma’s registration statements on Form F-3 and Form S-8, which relate to securities offerings and equity compensation plans.
For a company focused on immuno-oncology and antibody-engineering, SEC filings can provide additional detail on collaboration and licensing agreements with partners such as Sanofi and AstraZeneca, risk factor discussions, and descriptions of pipeline assets including IPH4502, lacutamab, monalizumab and ANKET®-based programs. Filings may also include information on share capital, voting rights, financing tools such as at-the-market programs, and other capital markets activities.
On Stock Titan, these documents are complemented by AI-powered summaries designed to help readers quickly understand the key points of lengthy filings. Users can review new Form 6-K submissions as they are furnished to the SEC’s EDGAR system, and use the summaries to navigate complex regulatory language, while still having access to the full original documents for detailed analysis.
Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, reported that its executive team will hold one-on-one investor meetings at the D. Boral Capital Global Conference in New York on May 7, 2026. The company highlights a portfolio of next-generation antibody therapeutics, including IPH4502, lacutamab and monalizumab, developed alone or in collaboration with partners such as AstraZeneca and Sanofi. Headquartered in Marseille with a U.S. office in Rockville, Innate is listed on Euronext Paris and Nasdaq and directs readers to its French and U.S. regulatory filings for detailed risk factors.
Innate Pharma reported encouraging interim results from the Phase 2 MATISSE trial of IPH5201 in resectable non-small cell lung cancer. The study combines IPH5201, a first-in-class anti-CD39 antibody, with durvalumab and platinum-based chemotherapy in previously untreated, resectable NSCLC.
In a pre-planned interim analysis of 40 patients, the combination showed higher pathological complete response rates than a benchmark of durvalumab plus chemotherapy alone. Pathological complete response reached 35.7% in tumors with PD-L1 ≥1% and 50% in tumors with PD-L1 ≥50%.
On the basis of these data, MATISSE continues enrolling patients whose tumors express PD-L1 ≥1%. The interim results will be presented in a Clinical Trials Plenary Session at the AACR Annual Meeting 2026, highlighting IPH5201’s potential role in enhancing anti-tumor immune responses in early-stage lung cancer.
Innate Pharma S.A. released an update on its capital structure and voting rights as of April 9, 2026. The company reports 93,860,680 shares outstanding, made up mainly of ordinary shares with small tranches of 2016 and 2017 preferred shares.
The company states it has 94,484,443 theoretical voting rights, used for regulatory threshold calculations in France, and 94,465,868 exercisable voting rights, which exclude treasury shares with suspended voting rights. The update helps clarify shareholder voting power ahead of any future corporate decisions.
Innate Pharma S.A. released an update on its capital structure and voting rights as of April 9, 2026. The company reports 93,860,680 shares outstanding, made up mainly of ordinary shares with small tranches of 2016 and 2017 preferred shares.
The company states it has 94,484,443 theoretical voting rights, used for regulatory threshold calculations in France, and 94,465,868 exercisable voting rights, which exclude treasury shares with suspended voting rights. The update helps clarify shareholder voting power ahead of any future corporate decisions.
Innate Pharma S.A. will hold its Annual General Meeting of shareholders at 10:30 a.m. CEST on May 21, 2026, at its headquarters in Marseille, France. The notice, agenda, proposed resolutions, and voting instructions were published in the French legal bulletin and are available on the company’s investor website.
The AGM will be broadcast live online, and a guided tour of the company’s laboratories will be organized the same day at 9:15 a.m. CEST for shareholders who register in advance. Only shareholders with shares recorded in an account at least five trading days before the meeting, and bearer shareholders providing a broker certificate, will be entitled to participate and vote.
Innate Pharma S.A. will hold its Annual General Meeting of shareholders at 10:30 a.m. CEST on May 21, 2026, at its headquarters in Marseille, France. The notice, agenda, proposed resolutions, and voting instructions were published in the French legal bulletin and are available on the company’s investor website.
The AGM will be broadcast live online, and a guided tour of the company’s laboratories will be organized the same day at 9:15 a.m. CEST for shareholders who register in advance. Only shareholders with shares recorded in an account at least five trading days before the meeting, and bearer shareholders providing a broker certificate, will be entitled to participate and vote.
Novo Nordisk A/S reports passive beneficial ownership of 4,718,727 ordinary shares of Innate Pharma. The filing states this position represents 5.03% of the class as of 03/31/2026 and shows sole voting and dispositive power over all 4,718,727 shares. The filing is an amendment to a Schedule 13G/A and is signed by Karsten Munk Knudsen, Chief Financial Officer, on 04/10/2026.
Innate Pharma S.A., a clinical-stage immuno-oncology company listed on Euronext Paris and Nasdaq, announced that Chief Operating Officer Yannis Morel will present at the AACR Oncology Industry Partnering Event in San Diego. The April 16, 2026 showcase session will allow Innate to highlight its oncology pipeline, including key assets such as IPH4502, a Nectin4 antibody-drug conjugate for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, developed with AstraZeneca, for non-small cell lung cancer. The company views this invitation as recognition of its clinical pipeline and an opportunity to engage directly with investors and industry partners.
Innate Pharma S.A., a clinical-stage biotechnology company developing cancer immunotherapies, reported that its executive team will participate in one-on-one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15–16, 2026.
The company highlights its portfolio of antibody-based therapies, including IPH4502, lacutamab and monalizumab, and notes ongoing collaborations with major partners such as AstraZeneca and Sanofi. The notice also reiterates that investors should refer to its French Universal Registration Document and Form 20-F for detailed risk factors.
Innate Pharma S.A. has filed its 2025 Universal Registration Document with the French market authority AMF and its 2025 Form 20-F annual report with the U.S. SEC, both covering the year ended December 31, 2025. These filings include the annual financial report, management report, corporate governance report, and statutory auditors’ report.
Innate Pharma is a clinical-stage biotechnology company focused on cancer immunotherapies, developing next-generation antibody-based drugs such as IPH4502, lacutamab and monalizumab, in collaboration with partners including AstraZeneca and Sanofi.
Innate Pharma S.A. files its Form 20‑F annual report, describing a clinical‑stage, oncology‑focused biotech developing immuno‑oncology antibodies, including checkpoint inhibitors and its ANKET® multi‑specific platform. Financial statements are prepared under IFRS Accounting Standards and presented in euros.
The report emphasizes that most product candidates are in early clinical or preclinical stages, with high development uncertainty, reliance on partners AstraZeneca and Sanofi, and significant dependence on additional financing. It highlights extensive regulatory, clinical, competitive and reimbursement risks, and notes orphan drug, fast track, PRIME and Breakthrough Therapy designations for lacutamab as important but not guaranteed paths to faster approval. Ordinary shares outstanding were 93,719,323 as of December 31, 2025.
Innate Pharma S.A. reported a 2025 net loss of €49.2 million, broadly in line with 2024, as revenue and other income fell 55% to €9.0 million mainly due to lower collaboration and licensing revenue from AstraZeneca and Sanofi.
Cash, cash equivalents, short-term investments and financial assets totaled €44.8 million as of December 31, 2025, giving an estimated cash runway only until the end of Q3 2026. Shareholders’ equity turned negative at €(21.7) million, and the company states there is substantial doubt about its ability to continue as a going concern while it pursues non-dilutive financing options.
R&D expenses declined 16% to €43.6 million as the pipeline was strategically refocused, including discontinuation of IPH6501, while key programs such as lacutamab, IPH4502 and partnered assets with AstraZeneca and Sanofi continue to advance toward significant data and regulatory milestones in 2026.